This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



belatacept (Nulojix®)


Reference No. 430

Publication date:
27/07/2012


Last review date:
30/08/2016

Appraisal information

belatacept (Nulojix®) 250 mg powder for concentrate for solution for infusion


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/05/2012
AWMSG meeting date: 20/06/2012
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1712
Ratification by Welsh Government: 23/07/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA481) NICE GUIDANCE ISSUED NOVEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download